These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 33159495)

  • 41. Functional classification of BRCA2 DNA variants by splicing assays in a large minigene with 9 exons.
    Acedo A; Hernández-Moro C; Curiel-García Á; Díez-Gómez B; Velasco EA
    Hum Mutat; 2015 Feb; 36(2):210-21. PubMed ID: 25382762
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Diagnostic mRNA splicing assay for variants in
    Wangensteen T; Felde CN; Ahmed D; Mæhle L; Ariansen SL
    Hered Cancer Clin Pract; 2019; 17():14. PubMed ID: 31143303
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pathogenicity evaluation of BRCA1 and BRCA2 unclassified variants identified in Portuguese breast/ovarian cancer families.
    Santos C; Peixoto A; Rocha P; Pinto P; Bizarro S; Pinheiro M; Pinto C; Henrique R; Teixeira MR
    J Mol Diagn; 2014 May; 16(3):324-34. PubMed ID: 24607278
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Accurate detection and quantification of epigenetic and genetic second hits in BRCA1 and BRCA2-associated hereditary breast and ovarian cancer reveals multiple co-acting second hits.
    Van Heetvelde M; Van Bockstal M; Poppe B; Lambein K; Rosseel T; Atanesyan L; Deforce D; Van Den Berghe I; De Leeneer K; Van Dorpe J; Vral A; Claes KBM
    Cancer Lett; 2018 Jul; 425():125-133. PubMed ID: 29580810
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Comprehensive splicing functional analysis of DNA variants of the BRCA2 gene by hybrid minigenes.
    Acedo A; Sanz DJ; Durán M; Infante M; Pérez-Cabornero L; Miner C; Velasco EA
    Breast Cancer Res; 2012 May; 14(3):R87. PubMed ID: 22632462
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Interpretation of BRCA2 Splicing Variants: A Case Series of Challenging Variant Interpretations and the Importance of Functional RNA Analysis.
    Nix P; Mundt E; Coffee B; Goossen E; Warf BM; Brown K; Bowles K; Roa B
    Fam Cancer; 2022 Jan; 21(1):7-19. PubMed ID: 33469799
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Two mutations of BRCA2 gene at exon and splicing site in a woman who underwent oncogenetic counseling.
    Pensabene M; Spagnoletti I; Capuano I; Condello C; Pepe S; Contegiacomo A; Lombardi G; Bevilacqua G; Caligo MA
    Ann Oncol; 2009 May; 20(5):874-8. PubMed ID: 19179552
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Identification of twenty-nine novel germline unclassified variants of BRCA1 and BRCA2 genes in 1400 Italian individuals.
    Santonocito C; Scapaticci M; Guarino D; Bartolini A; Minucci A; Concolino P; Scambia G; Paris I; Capoluongo E
    Breast; 2017 Dec; 36():74-78. PubMed ID: 29020660
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Characterization of a novel germline BRCA1 splice variant, c.5332+4delA.
    Yang C; Jairam S; Amoroso KA; Robson ME; Walsh MF; Zhang L
    Breast Cancer Res Treat; 2018 Apr; 168(2):543-550. PubMed ID: 29185120
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Quantitative Analysis of
    Farber-Katz S; Hsuan V; Wu S; Landrith T; Vuong H; Xu D; Li B; Hoo J; Lam S; Nashed S; Toppmeyer D; Gray P; Haynes G; Lu HM; Elliott A; Tippin Davis B; Karam R
    Front Oncol; 2018; 8():286. PubMed ID: 30101128
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Prevalence of BRCA1/BRCA2 mutations in a Brazilian population sample at-risk for hereditary breast cancer and characterization of its genetic ancestry.
    Fernandes GC; Michelli RA; Galvão HC; Paula AE; Pereira R; Andrade CE; Felicio PS; Souza CP; Mendes DR; Volc S; Berardinelli GN; Grasel RS; Sabato CS; Viana DV; Mauad EC; Scapulatempo-Neto C; Arun B; Reis RM; Palmero EI
    Oncotarget; 2016 Dec; 7(49):80465-80481. PubMed ID: 27741520
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Skipping Nonsense to Maintain Function: The Paradigm of
    Meulemans L; Mesman RLS; Caputo SM; Krieger S; Guillaud-Bataille M; Caux-Moncoutier V; Léone M; Boutry-Kryza N; Sokolowska J; Révillion F; Delnatte C; Tubeuf H; Soukarieh O; Bonnet-Dorion F; Guibert V; Bronner M; Bourdon V; Lizard S; Vilquin P; Privat M; Drouet A; Grout C; Calléja FMGR; Golmard L; Vrieling H; Stoppa-Lyonnet D; Houdayer C; Frebourg T; Vreeswijk MPG; Martins A; Gaildrat P
    Cancer Res; 2020 Apr; 80(7):1374-1386. PubMed ID: 32046981
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Spectrum of genetic variants of BRCA1 and BRCA2 in a German single center study.
    Meisel C; Sadowski CE; Kohlstedt D; Keller K; Stäritz F; Grübling N; Becker K; Mackenroth L; Rump A; Schröck E; Arnold N; Wimberger P; Kast K
    Arch Gynecol Obstet; 2017 May; 295(5):1227-1238. PubMed ID: 28324225
    [TBL] [Abstract][Full Text] [Related]  

  • 54. An immune-centric exploration of BRCA1 and BRCA2 germline mutation related breast and ovarian cancers.
    Przybytkowski E; Davis T; Hosny A; Eismann J; Matulonis UA; Wulf GM; Nabavi S
    BMC Cancer; 2020 Mar; 20(1):197. PubMed ID: 32164626
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Assessing the RNA effect of 26 DNA variants in the BRCA1 and BRCA2 genes.
    Menéndez M; Castellsagué J; Mirete M; Pros E; Feliubadaló L; Osorio A; Calaf M; Tornero E; del Valle J; Fernández-Rodríguez J; Quiles F; Salinas M; Velasco A; Teulé A; Brunet J; Blanco I; Capellá G; Lázaro C
    Breast Cancer Res Treat; 2012 Apr; 132(3):979-92. PubMed ID: 21735045
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A specific GFP expression assay, penetrance estimate, and histological assessment for a putative splice site mutation in BRCA1.
    Southey MC; Tesoriero A; Young MA; Holloway AJ; Jenkins MA; Whitty J; Misfud S; kConFab ; McLachlan SA; Venter DJ; Armes JE
    Hum Mutat; 2003 Jul; 22(1):86-91. PubMed ID: 12815598
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Naturally occurring BRCA2 alternative mRNA splicing events in clinically relevant samples.
    Fackenthal JD; Yoshimatsu T; Zhang B; de Garibay GR; Colombo M; De Vecchi G; Ayoub SC; Lal K; Olopade OI; Vega A; Santamariña M; Blanco A; Wappenschmidt B; Becker A; Houdayer C; Walker LC; López-Perolio I; Thomassen M; Parsons M; Whiley P; Blok MJ; Brandão RD; Tserpelis D; Baralle D; Montalban G; Gutiérrez-Enríquez S; Díez O; Lazaro C; ; Spurdle AB; Radice P; de la Hoya M
    J Med Genet; 2016 Aug; 53(8):548-58. PubMed ID: 27060066
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Hereditary Breast and Ovarian Cancer Syndrome: Moving Beyond BRCA1 and BRCA2.
    Hoang LN; Gilks BC
    Adv Anat Pathol; 2018 Mar; 25(2):85-95. PubMed ID: 28914618
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Imprecise Medicine: BRCA2 Variants of Uncertain Significance (VUS), the Challenges and Benefits to Integrate a Functional Assay Workflow with Clinical Decision Rules.
    Jimenez-Sainz J; Jensen RB
    Genes (Basel); 2021 May; 12(5):. PubMed ID: 34065235
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Alternative mRNA splicing can attenuate the pathogenicity of presumed loss-of-function variants in BRCA2.
    Mesman RLS; Calléja FMGR; de la Hoya M; Devilee P; van Asperen CJ; Vrieling H; Vreeswijk MPG
    Genet Med; 2020 Aug; 22(8):1355-1365. PubMed ID: 32398771
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.